An observational study in Hemophilia A and Hemophilia B, sponsored by Swedish Orphan Biovitrum. Completed at 16 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by Swedish Orphan Biovitrum · Observational
The purpose of this study is to validate the newly developed Hemophilia Functional Ability Scoring Tool (Hemo-FAST), which is a fast and simple scoring in haemophilia able to assess patient-reported functional mobility.
The purpose of this study is to validate the newly developed Hemophilia Functional Ability Scoring Tool (Hemo-FAST), which is a fast and simple scoring in haemophilia able to assess patient-reported functional mobility for adult haemophilia patients.
866 studies on the registry are indexed under Hemophilia A; 137 are open to participants now.
This study's enrollment of 180 is above the median of 80 across 314 observational studies indexed under Hemophilia A.
Browse Hemophilia A studies →Swedish Orphan Biovitrum is the lead sponsor of 78 studies on the registry; 4 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients will be enrolled from 10-15 haemophilia treatment centres (HTCs) across France. The lower age limit of 18 years has been chosen because Hemo-FAST was developed to be used among the adult population. Age is an important contributor to the development of joint damage. Enrolment will therefore be targeted so that there will be similar numbers of patients enrolled across three age groups: 18-29, 30-44 and ≥ 45-years old.
Inclusion Criteria:A patient must fulfil the following criteria in order to be included in the study:
Exclusion Criteria:
The presence of any of the following criteria will exclude a patient from inclusion in the study:
Joint examination with Hemophilia Joint Health Score (HJHS)
Psychometric validation of the Hemophilia Functional Ability Scoring Tool (Hemo-FAST).
Statistical analysis to confirm the psychometric validation of the Hemo-FAST questionnaire
Time frame: Baseline
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Swedish Orphan Biovitrum